相关实验视频

Updated: Jan 9, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

在中印度患者中可操作的CYP2D6 / CYP2C19变异的药物遗传变异和临床影响,这些患者有常见的精神障碍

Santenna Chenchula¹, Atal Shubham¹, Rozatkar Abhijit²

¹Department of Pharmacology, AIIMS Bhopal, India.

Frontiers in pharmacology

|December 11, 2025

概括

中印人中常见的CYP2D6和CYP2C19的药物遗传变异,影响抗抑郁药的有效性. 将药物遗传学纳入精神病治疗可以改善治疗结果并减少不良事件.

科学领域:

药物遗传学药物遗传学
精神病学药物基因组学
药物代谢药物代谢

背景情况:

基因变异CYP2D6和CYP2C19显著影响抗抑郁药代谢,疗效和安全性.
关于这些药物遗传变异在中印度人口中的流行情况的数据有限.

研究的目的:

确定中印度人中CYP2D6和CYP2C19临床可操作的Tier-1等位基因,基因型和代谢器表型的频率.
评估这些变异在患有常见精神障碍 (CMD) 的患者中的临床相关性.

主要方法:

使用KASP qPCR试验对509名患有抑郁症和焦虑症的成年患者进行基因定型.
使用TaqMan qPCR试验确定CYP2D6拷贝数变异 (CNVs).

主要成果:

观察到可起作用的CYP2D6 (*10, *41, *4) 和CYP2C19 (*2, *17) 等位基因的高流行率.
在CYP2D6的46.2%和CYP2C19.2的74.2%中发现了非正常的代谢器表型.
86%的参与者至少有一种临床可操作的药物遗传表型,其中7.5%携带CYP2D6和20.6%携带CYP2C19变体,需要基于指南的干预.

结论:

在中印度人口中存在可操作的CYP2D6和CYP2C19变体的高流行率.
药物遗传测试的整合对于优化印度精神病学环境中的抗抑郁药物治疗至关重要.
这种方法可以提高治疗效率,并尽量减少不良药物事件.

关键词:

在CPIC中,您可以使用CPIC.在CYP2C19中.在CYP2D6中.抗抑郁药是一种抗抑郁药.常见的精神障碍常见的精神障碍副本号码的变化副本号的变化印度人口印度人人口.药物遗传学药物遗传学

更多相关视频

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Identification and Classification of Position-specific GABA_A Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Human Genetics

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Factors Affecting Drug Biotransformation: Biological

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...